Biotech Firm Alumis Reduces IPO Ambitions, Yet Secures $250M for Clinical Trials
Immunology and inflammation biotechnology company Alumis has recently entered the public markets, securing $250 million in pivotal funding to advance clinical trials of its leading drug candidate. The company aims to demonstrate the efficacy of its small molecule in treating plaque psoriasis, a competitive area currently targeted by several pharmaceutical giants. Alumis’ entry into Nasdaq […]